The House resolution designates May 5 to 11, 2024, as Tardive Dyskinesia Awareness Week in Minnesota. It highlights the connection between the use of dopamine receptor blocking agents (DRBAs), commonly prescribed for serious mental health and gastrointestinal disorders, and the risk of developing tardive dyskinesia (TD), an involuntary movement disorder affecting approximately 600,000 people in the U.S. The resolution emphasizes the importance of raising awareness about TD, as many individuals remain undiagnosed, and even mild symptoms can lead to significant physical, social, and emotional challenges.

Furthermore, the resolution calls for increased monitoring and screening for TD among patients taking DRBAs, as recommended by the American Psychiatric Association. It also notes that clinical research has resulted in FDA-approved treatments for adults with TD. By designating this week, the Minnesota Legislature aims to enhance public and medical community awareness of tardive dyskinesia, encouraging individuals to educate themselves about the disorder and its implications.